SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

US Supreme Court blocks bid to overturn lower court ruling | District court found in 2023 that the generic would infringe patents owned by a Bausch subsidiary | Blockbuster drug Xifaxan is used to treat IBS with diarrhoea, and a liver-related brain disorder.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Federal Circuit tosses $59m trade secrets judgment against EOFlow

29 May 2026 A US appeals court has thrown out a jury verdict against a South Korean medical device company, ruling that Insulet waited too long to bring its trade secret misappropriation claim.

Americas

AI, anxiety, and antibodies: The issues dominating life sciences

26 May 2026 Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.

Americas

How should in-house teams adopt AI? ‘Carefully’, says secrets expert

26 May 2026 Ahead of WIPR Trade Secrets West, Cooley partner Heidi Keefe says that for legal teams, caution—not business pressure—should be the priority.

More features

Federal Circuit tosses $59m trade secrets judgment against EOFlow

Neal Gerber Eisenberg expands in Chicago with new litigator

European court backs AstraZeneca unit in blood cancer combo dispute

Takeda’s China IP head: What pharma is still getting wrong

Boehringer Ingelheim adds ex-Teva executive to patent team

AI, anxiety, and antibodies: The issues dominating life sciences

UPC judge: ‘Expectations of you as a woman are the challenge’

How should in-house teams adopt AI? ‘Carefully’, says secrets expert

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

More on this story

Editor's picks

Editor's picks

More features